Operational Costs Compared: SG&A Analysis of Jazz Pharmaceuticals plc and Madrigal Pharmaceuticals, Inc.

SG&A Expenses: Jazz vs. Madrigal's Decade of Strategy

__timestampJazz Pharmaceuticals plcMadrigal Pharmaceuticals, Inc.
Wednesday, January 1, 201440611400015746000
Thursday, January 1, 201544911900013392000
Friday, January 1, 20165028920009290000
Sunday, January 1, 20175441560007672000
Monday, January 1, 201868353000015293000
Tuesday, January 1, 201973694200022648000
Wednesday, January 1, 202085423300021864000
Friday, January 1, 2021145168300037318000
Saturday, January 1, 2022141696700048130000
Sunday, January 1, 20231343105000108146000
Loading chart...

In pursuit of knowledge

A Decade of SG&A: Jazz vs. Madrigal

In the competitive landscape of pharmaceuticals, operational efficiency is key. Over the past decade, Jazz Pharmaceuticals plc and Madrigal Pharmaceuticals, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Jazz Pharmaceuticals has consistently maintained higher SG&A expenses, peaking in 2021 with a staggering 1.45 billion USD, reflecting a strategic investment in growth and market expansion. In contrast, Madrigal Pharmaceuticals, with a more conservative approach, saw its SG&A expenses rise significantly in 2023, reaching 108 million USD, marking a tenfold increase from 2014. This divergence highlights the varied paths companies take in scaling operations and managing costs. As the industry evolves, these financial strategies will play a crucial role in shaping their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025